Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | GSK3A | P49840 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MITF | O75030 | 1/20 | 0.38 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.38 |
| ▸ | PIN4 | Q9Y237 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20952658 | 0.84 | KIT (0.39) | MAPK1MEN1TSHRKMT2A | |
| SCHEMBL22400121 | 0.83 | MEN1 (0.45) | MAPK1MEN1TSHRKMT2AHSD17B10 | |
| SCHEMBL908777 | 0.81 | MAPK1 (0.50) | MAPK1PKMATMHSD17B10GSK3A | |
| SCHEMBL22400120 | 0.81 | NTRK1 (0.37) | MAPK1MEN1TSHRKMT2ASRC | |
| SCHEMBL13819931 | 0.79 | MAPK1 (0.48) | MAPK1MEN1TSHRKMT2APKM | |
| SCHEMBL26328680 | 0.79 | NTRK1 (0.38) | MAPK1MEN1TSHRKMT2AHSD17B10 | |
| SCHEMBL19010780 | 0.78 | MAPK1 (0.47) | MAPK1PKMATMHSD17B10GSK3A | |
| SCHEMBL14788175 | 0.78 | MAPK1 (0.51) | MAPK1PKMATMHSD17B10GSK3A | |
| SCHEMBL20438069 | 0.78 | NTRK1 (0.36) | MAPK1MEN1TSHRKMT2A | |
| SCHEMBL11223440 | 0.78 | MAPK1 (0.47) | MAPK1MEN1TSHRKMT2APKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110546147-B | Phenoxyquinazoline compounds and their use in the treatment of cancer | 阿斯利康(瑞典)有限公司 | 2023-05-23 | — | — | CN | disclosed |
| CN-110573505-B | C 5 -anilinoquinazoline compounds and their use in the treatment of cancer | 阿斯利康(瑞典)有限公司 | 2023-04-11 | — | — | CN | disclosed |
| EP-3615526-B1 | PHENOXYQUINAZOLINE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2021-08-04 | — | — | EP | disclosed |
| EP-3615522-B1 | C5-ANILINOQUINAZOLINE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2021-08-04 | — | — | EP | disclosed |
| US-11053223-B2 | Phenoxyquinazoline compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2021-07-06 | — | — | US | disclosed |
| US-10829479-B2 | C5-anilinoquinazoline compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2020-11-10 | — | — | US | disclosed |
| US-20200223828-A1 | PHENOXYQUINAZOLINE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA UK LIMITED (GB) | 2020-07-16 | — | — | US | disclosed |
| EP-3615526-A1 | PHENOXYQUINAZOLINE COMPOUNDS AND THEIR USE IN TREATING CANCER | Astrazeneca (SE) | 2020-03-04 | — | — | EP | disclosed |
| EP-3615522-A1 | C5-ANILINOQUINAZOLINE COMPOUNDS AND THEIR USE IN TREATING CANCER | Astrazeneca (SE) | 2020-03-04 | — | — | EP | disclosed |
| CN-110573505-A | C5-anilinoquinazoline compounds and their use in the treatment of cancer | 阿斯利康(瑞典)有限公司 | 2019-12-13 | — | — | CN | disclosed |
| US-20140031329-A1 | SUBSTITUTED DIHYDROPYRAZOLONES FOR TREATING CARDIOVASCULAR AND HEMATOLOGICAL DISEASES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-01-30 | — | — | US | disclosed |
| US-20140031329-A1 | SUBSTITUTED DIHYDROPYRAZOLONES FOR TREATING CARDIOVASCULAR AND HEMATOLOGICAL DISEASES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-01-30 | — | — | US | disclosed |
| US-8389520-B2 | Substituted dihydropyrazolones for treating cardiovascular and hematological diseases | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-03-05 | — | — | US | disclosed |
| US-8389520-B2 | Substituted dihydropyrazolones for treating cardiovascular and hematological diseases | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-03-05 | — | — | US | disclosed |
| EP-2546253-A1 | SUBSTITUTED DIHYDROPYRAZOLONES FOR THE TREATMENT OF CARDIOVASCULAR AND HEMATOLOGICAL DISEASES | Bayer Intellectual Property GmbH (DE) | 2013-01-16 | — | — | EP | disclosed |
| US-20120121727-A1 | SUBSTITUTED DIHYDROPYRAZOLONES FOR TREATING CARDIOVASCULAR AND HEMATOLOGICAL DISEASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-05-17 | — | — | US | disclosed |
| US-20120121727-A1 | SUBSTITUTED DIHYDROPYRAZOLONES FOR TREATING CARDIOVASCULAR AND HEMATOLOGICAL DISEASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-05-17 | — | — | US | disclosed |
| EP-2383269-A2 | Substituted Dihydropyrazolones for the treatment of cardiovascular diseases | Bayer Pharma AG (DE) | 2011-11-02 | — | — | EP | disclosed |
| US-20100305085-A1 | SUBSTITUTED DIHYDROPYRAZOLONES FOR TREATING CARDIOVASCULAR AND HEMATOLOGICAL DISEASES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-12-02 | — | — | US | disclosed |
| US-20100305085-A1 | SUBSTITUTED DIHYDROPYRAZOLONES FOR TREATING CARDIOVASCULAR AND HEMATOLOGICAL DISEASES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140031329-A1 | SUBSTITUTED DIHYDROPYRAZOLONES FOR TREATING CARDIOVASCULAR AND HEMATOLOGICAL DISEASES | THPO, PFKP, DCK | MAPK1 1657/4885MEN1 3430/4885TSHR 4799/4885 |
| US-10829479-B2 | C5-anilinoquinazoline compounds and their use in treating cancer | KIT, C5, C9 | MAPK1 1530/4885MEN1 110/4885TSHR 2693/4885 |
| US-11053223-B2 | Phenoxyquinazoline compounds and their use in treating cancer | KIT, ABL1, RB1 | MAPK1 1169/4885MEN1 643/4885TSHR 2602/4885 |
| US-20200223828-A1 | PHENOXYQUINAZOLINE COMPOUNDS AND THEIR USE IN TREATING CANCER | KIT, ABL1, RB1 | MAPK1 1169/4885MEN1 643/4885TSHR 2602/4885 |
| US-20100305085-A1 | SUBSTITUTED DIHYDROPYRAZOLONES FOR TREATING CARDIOVASCULAR AND HEMATOLOGICAL DISEASES | THPO, PFKP, HPGDS | MAPK1 1183/4885MEN1 2510/4885TSHR 4833/4885 |
| US-20120121727-A1 | SUBSTITUTED DIHYDROPYRAZOLONES FOR TREATING CARDIOVASCULAR AND HEMATOLOGICAL DISEASES | THPO, PFKP, DCK | MAPK1 1657/4885MEN1 3430/4885TSHR 4799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.